摘要
2019年底,湖北武汉暴发了2019新型冠状病毒感染疾病(COVID-19),并快速在全国蔓延,且在多个国家发现病例。其感染病例和死亡病例在短时间内快速超过重症急性呼吸综合征(SARS),给中国带来了不可估量的损失。中国科研人员在短时间内,快速锁定病原体为2019-nCoV(或hCoV-19或SARS-CoV-2),并且在不同层面开展了相关抗病毒药物的研发工作。本文介绍了抗2019-nCoV新药研发的现状。同时,鉴于突发病原体的药物研发过程相对迟缓,我们建议对于潜在流行可能性的病原体,其药物研发要具有前瞻性,国家层面要推进广谱药物的研发和临床试验,以应对可能出现的疫情风险。
At the end of 2019,an outbreak of 2019 new coronavirus infectious disease(COVID-19)in Wuhan spread rapidly in China and reported cases in other countries.The number of infected cases and deaths quickly exceeded Severe Acute Respiratory Syndrome(SARS)in a short period of time,resulting in incalculable losses to China.Chinese researchers have quickly identified the pathogen,2019-nCoV(or SARS-CoV-2 or HCoV-19)and carried out the research and development of antiviral drugs at different levels.This article briefly reviews the current advancement of research and development of new therapeutics against 2019-nCoV infection.Given that the progress of research and development of antiviral drugs against the emerging and reemerging pathogens is relatively backwarded,we suggest that the research and development of antivirals against pathogens with pandemic or epidemic potential should be carried out in advance before the occurrence of the outbreaks.At the national level,we should promote the research and development of broad-spectrum antivirals and clinical trials to combat the pathogens with epidemic risk.
作者
刘奇
夏帅
姜世勃
LIU Qi;XIA Shuai;JIANG Shibo(Integrated Lab of Pathogen Biology,College of Basic Medical Sciences,Dali University,Dali 671000,Yunnan,China;Key Laboratory of Medical Molecular Virology of MOE/MOH,School of Basic Medical Sciences,Fudan University,Shanghai 200032,China)
出处
《中国临床药理学与治疗学》
CAS
CSCD
2020年第3期241-245,共5页
Chinese Journal of Clinical Pharmacology and Therapeutics
作者简介
刘奇,男,博士,副教授,从事病毒感染与免疫方面的研究,Tel:0872-2257115,E-mail:qiliu@aliyun.com;通讯作者:姜世勃,男,复旦大学教授,博士生导师,病原微生物研究所所长,复旦-锦波功能蛋白联合研究中心主任,曾是武汉大学、复旦大学、广州第一军医大学、西安第四军医大学、中国军事医学科学院的客座教授,长期从事抗艾滋病病毒和冠状病毒药物和疫苗的研究工作,国际病毒融合/进入抑制剂研究领域的主要开创者及领跑者,在Nature,Science,Cell,Lancet等杂志发表SCI论文458篇,申请美国专利36项(授权25项)和中国及PCT专利54项(授权18项),其中11项已成功转让,多项产品已上市,Tel:021-54237673,E-mail:shibojiang@fudan.edu.cn。
